TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10225582
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg, every 12 h)
Study: 10225582
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral therapy
Study: 30499929
Drug: In the
Normalized name: Skin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Classroom Web site (treatment group)
Study: 25751673
Drug: Isotonic intravenous
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic intravenous fluids (sodium chloride, 0.9%, and dextrose, 5%)
Study: 25751673
Drug: Hypotonic intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic intravenous fluids (sodium chloride, 0.45%, and dextrose, 5%)
Study: 25751673
Drug: Hypotonic intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic intravenous fluids
Study: 25751673
Drug: Isotonic intravenous
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic intravenous fluids
Study: 24331798
Drug: Tirofiban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (10 µg/kg bolus within 3 min followed by 0.10‐0.15 µg×kg(‐1)×min(‐1) for 36 h i.v.)
Study: 20347467
Drug: Abstinence with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence with transdermal nicotine patch (TNP)
Study: 18554238
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg entecavir
Study: 21794296
Drug: Overall NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall NSAID therapy
Study: 10971602
Drug: Brain-derived neurotrophic
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain-derived neurotrophic factor (BDNF) 25 microg/kg daily
Study: 8285335
Drug: 4 l.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l.min‐1 of oxygen by nasal catheter
Study: 3104180
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patches delivering 10 mg/24 hours
Study: 24786196
Drug: Jitai tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitai tablet treatment
Study: 20466951
Drug: Dental practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental practitioner advice and brief counseling intervention including nicotine replacement therapy
Study: 12554916
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K prophylaxis in severely ill patients on extended periods of antibiotics and inadequate diet
Study: 6366137
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of chemotherapy
Study: 29787831
Drug: Oleoylethanolamide (OEA)
Normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleoylethanolamide (OEA) 125 mg capsules, two capsules daily for 60 days
Study: 17557985
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) high in catechins (583 mg of catechins per day)
Study: 17557985
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (96 mg of catechins per day)
Study: 12189112
Drug: bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (5 mg/d)
Study: 12189112
Drug: enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (10 mg/d)
Study: 12189112
Drug: nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine retard (20 mg/day)
Study: 7661122
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg beta-carotene daily for 3 weeks
Study: 7661122
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg beta-carotene oral dose
Study: 1096541
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (parenteral)
Study: 1096541
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (penfluridol and flupenthixol decanoate)
Study: 25950433
Drug: 2011/12 seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2011/12 seasonal influenza DNA vaccine prime
Study: 21563210
Drug: Anticholinergic medication
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic medication with or without behavioral therapy
Study: 18698222
Drug: Valsartan/Lisinopril 320/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Lisinopril 320/20 mg
Study: 14743888
Drug: Oxaliplatin in
Normalized name: oxaliplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin in combination with 5-fluoro-uracil (5-FU) and leucovorin
Study: 14743888
Drug: Oral prodrugs
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prodrugs of 5-FU (capecitabine and uracil)
Study: 14743888
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies and small molecules targeting EGFR and VEGF
Study: 10899744
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 300 mg extractum Valerianae radix siccum dragées LI 156
Study: 10899744
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 5 mg oxazepam dragées
Study: 8970248
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% solution
Study: 8970248
Drug: Betaxolol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.25% suspension
Study: 6344893
Drug: Indoprofen 400
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 400 mg (i.v. bolus + 2-h infusion)
Study: 6344893
Drug: Indoprofen 400
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 400 mg (i.v. bolus alone)
Study: 26420269
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (dorsolateral prefrontal cortex group)
Study: 26420269
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (cingulo-opercular network group)
Study: 26420269
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (motor primary cortex group)
Study: 24144788
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice daily with concomitant aspirin
Study: 24144788
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with concomitant aspirin
Study: 24144788
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice daily without concomitant aspirin
Study: 24144788
Drug: Warfarin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin without concomitant aspirin
Study: 17466461
Drug: Routine burn
Normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine burn rehabilitation treatment
Study: 9711448
Drug: Orlistat 360
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 360 mg/day for 12 weeks
Study: 2677374
Drug: H142 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H142 at 1.0 mg/kg/h
Study: 2677374
Drug: H142 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H142 at 5.0 mg/kg/h
Study: 2677374
Drug: H142 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: H142 (all doses)
Study: 356925
Drug: multivitamin‐electrolyte‐preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: multivitamin‐electrolyte‐preparation
Study: 30076614
Drug: Terlipressin (2-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2-12 mg/day)
Study: 31007053
Drug: Group-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based occupational therapy (Group BOT, n=43)
Study: 28027937
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN)
Study: 25998582
Drug: Tamsulosin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 400 μg
Study: 21712498
Drug: rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (10 mg/day)
Study: 15618271
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor antagonist (540 mg oral fexofenadine hydrochloride; Allegra)
Study: 15618271
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no H1 receptor antagonist)
Study: 12518534
Drug: Eradication of
Normalized name: Combinations for eradication of Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication of Helicobacter pylori infection using triple therapy (pantoprazole + amoxicillin + clarithromycin)
Study: 9578506
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (18 units/m2 per week divided into daily s.c. doses) for 1 year
Study: 9578506
Drug: IGF‐I generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I generation test after GH injection
Study: 7645033
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g treatment group (1.0 g b.i.d.)
Study: 7645033
Drug: MMF 3
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3 g treatment group (1.5 g b.i.d.)
Study: 7645033
Drug: Azathioprine group
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine group (1-2 mg/kg/day)
Study: 7645033
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g treatment group
Study: 7645033
Drug: MMF 3
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3 g treatment group
Study: 2694923
Drug: 4 capsules
Normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules (1.26 g omega-3 fatty acids)
Study: 2694923
Drug: 8 capsules
Normalized name: INGREZZA 40 MG / 80 MG Starter Pack, 28 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 capsules (2.52 g omega-3 fatty acids)
Study: 2694923
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil (4 capsules)
Study: 582710
Drug: Glucametacin (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucametacin (420 mg daily)
Study: 31564841
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained daily living and routines)
Study: 7588829
Drug: Gentamicin 4
Normalized name: gentamicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4 mg/kg q 24h i.v.
Study: 7588829
Drug: Gentamicin 1.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.33 mg/kg q 8h i.v. (thrice-daily)
Study: 7588829
Drug: Netilmicin 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 5.5 mg/kg q 24h i.v.
Study: 2378175
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse methylprednisolone 1000 mg
Study: 2378175
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse methylprednisolone 250 mg
Study: 2378175
Drug: Both dosages
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosages of intravenous methylprednisolone
Study: 31801940
Drug: Ofatumumab (300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years)
Study: 23497636
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg idursulfase beta infusions
Study: 23497636
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg idursulfase beta infusions
Study: 23497636
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator infusions
Study: 9210530
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone supplementation (rhGH, 0.15 mg/kg/d)
Study: 9210530
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with adjuvant rhGH
Study: 3519885
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) and hydrocortisone (HC) after TAM therapy
Study: 29127492
Drug: 0.2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/kg dexmedetomidine (Dex-0.2 group)
Study: 29127492
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg dexmedetomidine (Dex-0.5 group)
Study: 25706950
Drug: Usual family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual family based treatment (FBT)
Study: 23237107
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg/day or 20 mg/day or atorvastatin 80 mg/day for 12 weeks
Study: 15556325
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 30 mg before surgery
Study: 15556325
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection before surgery
Study: 15556325
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 30 mg after surgery
Study: 8908233
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection after surgery
Study: 9322804
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methimazole (MMI) + 1.5 micrograms 1 alpha (OH)D3 (group B)
Study: 9322804
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methimazole (MMI) (group A)
Study: 30229852
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (rhPro-UK after Solitaire scaffold)
Study: 24924486
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/day for six months
Study: 15885696
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mebendazole (MBZ)
Study: 8213600
Drug: Intranasal propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal propranolol spray (5 mg/puff)
Study: 3325934
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ciprofloxacin orally
Study: 3619432
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ciprofloxacin intravenously
Study: 3619432
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin orally
Study: 30558006
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (HR) group, infused at a rate of 0.25 μg/kg/min, adjusted by 0.05 μg/kg/min as needed.
Study: 30558006
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (LR) group, infused at a rate of 0.05 μg/kg/min.
Study: 30558006
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (HR) group.
Study: 30558006
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (LR) group.
Study: 25042870
Drug: 1mg oral
Normalized name: AXITINIB 1MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg oral dose of risperidone
Study: 22180560
Drug: Lamivudine dosing
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine dosing according to WHO weight band
Study: 22180560
Drug: Lamivudine dosing
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine dosing according to FDA label
Study: 20600017
Drug: pegylated interferon‐alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated interferon‐alfa‐2a (Peg‐IFNalfa‐2a) 180 µg/wk
Study: 20600017
Drug: albinterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: albinterferon alfa‐2b (albIFN) 900 µg every 2 weeks
Study: 20600017
Drug: albinterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: albinterferon alfa‐2b (albIFN) 1200 µg every 2 weeks
Study: 18235117
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 30,000 U subcutaneously once weekly for 24 weeks
Study: 31513163
Drug: Enhanced external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced external counterpulsation therapy during standard drug therapy (study group)
Study: 31513163
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug therapy (control group)
Study: 28292320
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg three times a day
Study: 26721135
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling combined with element calcium (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Study: 26721135
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Study: 11981075
Drug: i.v. calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. calcium folinate (50 mg/week)
Study: 11981075
Drug: oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral calcium folinate (50 mg/week)
Study: 11981075
Drug: oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral folic acid (45 mg/week)
Study: 9615260
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg daily for 12 months (group A)
Study: 383103
Drug: EMD 21657
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 21657 (3X300 mg)
Study: 31487383
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus prednisone (0.5 or 1.0 mg/kg/day, tapered over 3 or 6 months)
Study: 31487383
Drug: Prednisone alone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone alone (1.0 or 1.5 mg/kg/day, tapered over 12 or 18 months)
Study: 26016150
Drug: Palliative external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative external beam radiotherapy with hypofractionation regimes (3 fractions of 6.5 Gy for a total dose of 19.5 Gy, 4 fractions of 6.5 Gy for a total dose of 26 Gy) and standard treatment schedule (total dose of 26 Gy)
Study: 11127100
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole vaginal gel (5 g twice daily for five days)
Study: 11127100
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (500 mg twice daily for seven days)
Study: 9324103
Drug: Alpha1‐adrenoreceptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1‐adrenoreceptor blocker (bunazosin)
Study: 9324103
Drug: Beta1‐adrenoreceptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta1‐adrenoreceptor blocker (metoprolol)
Study: 27048670
Drug: Vitamin C/E
Normalized name: vitamin C/elderberry fruit/Echinacea purpurea 90 mg-100 mg-50 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C/E complex supplementation (100 IU of vitamin E + 500 mg of vitamin C) twice per day during radiotherapy
Study: 24096631
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (2 weeks)
Study: 24096631
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (8 weeks)
Study: 20679159
Drug: Best-tasting solution
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best-tasting solution
Study: 17357307
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis solutions with low content of glucose degradation products
Study: 17357307
Drug: Amino acid‐based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid‐based, icodextrin‐based or glycerol‐based dialysis solution
Study: 17357307
Drug: Intraperitoneal drugs
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal drugs
Study: 12661776
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day) for 2 years
Study: 10588313
Drug: Grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 400 mg od for 10 days
Study: 10719007
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg bd for 10 days